Selective Targeting of eIF4A by Hippuristanol
Author Information
Author(s): Lisa Lindqvist, Monika Oberer, Mikhail Reibarkh, Regina Cencic, Marie-Eve Bordeleau, Emily Vogt, Assen Marintchev, Junichi Tanaka, Francois Fagotto, Michael Altmann, Gerhard Wagner, Jerry Pelletier
Primary Institution: McGill University
Hypothesis
Can hippuristanol selectively inhibit the DEAD box RNA helicase eIF4A?
Conclusion
Hippuristanol selectively inhibits eIF4A's RNA binding and ATPase activities, providing insights into targeting RNA helicases for pharmacological intervention.
Supporting Evidence
- Hippuristanol binds to specific regions of eIF4A, affecting its function.
- Mutations in eIF4A can alter its sensitivity to hippuristanol.
- eIF4A's helicase activity is essential for translation initiation.
- Hippuristanol does not inhibit ATP binding to eIF4A.
- eIF4A and eIF4AII are functionally interchangeable in translation.
- Hippuristanol's effects were observed in both in vitro and in vivo systems.
Takeaway
Hippuristanol is a natural product that can stop a specific protein, eIF4A, from working properly, which helps scientists understand how to target similar proteins in the future.
Methodology
The study involved NMR experiments to identify the binding site of hippuristanol on eIF4A and assessed its effects on RNA binding and ATPase activity.
Limitations
The study primarily focuses on in vitro experiments, which may not fully represent in vivo conditions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website